UK Markets open in 7 hrs 48 mins

Global Transdermal Drug Delivery System Market (2021 to 2026) - by Application, End-user and Region

·8-min read

Dublin, Oct. 05, 2021 (GLOBE NEWSWIRE) -- The "Transdermal Drug Delivery System Market Research Report by Application, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Transdermal Drug Delivery System Market size was estimated at USD 6,094.32 Million in 2020 and expected to reach USD 6,369.32 Million in 2021, at a Compound Annual Growth Rate (CAGR) 4.78% to reach USD 8,065.71 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Transdermal Drug Delivery System to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Application, the Transdermal Drug Delivery System Market was studied across Cardiovascular Diseases, Central Nervous System Disorders, Hormonal Applications, Pain Management, and Transdermal Estrogen Therapy.

  • Based on Type, the Transdermal Drug Delivery System Market was studied across Transdermal Patches and Transdermal Semisolids. The Transdermal Patches is further studied across Drug-In-Adhesive Patches, Matrix Patches, Microneedle Patches, and Reservoir Membrane Patches. The Transdermal Semisolids is further studied across Gels, Ointments, and Sprays.

  • Based on End User, the Transdermal Drug Delivery System Market was studied across Home Care Settings and Hospitals & Clinics.

  • Based on Region, the Transdermal Drug Delivery System Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Transdermal Drug Delivery System Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Transdermal Drug Delivery System Market, including 3M Company, Bayers AG, Boehringer Ingelheim International GmbH, Endo International, Inc., Glaxosmithkline PLC, Hisamitsu Pharmaceutical Co., Inc., IBSA Farmaceutici Italia Srl, Johnson & Johnson, Katecho, LLC, Lavipharm S.A., Lead Chemical Co.,Ltd., Luye Pharma Group, Manchester BIOGEL, Nitto Denko Corporation, Novartis International AG, Nutriband Inc., UCB S.A., and Viatris Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Transdermal Drug Delivery System Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Transdermal Drug Delivery System Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Transdermal Drug Delivery System Market?
4. What is the competitive strategic window for opportunities in the Global Transdermal Drug Delivery System Market?
5. What are the technology trends and regulatory frameworks in the Global Transdermal Drug Delivery System Market?
6. What is the market share of the leading vendors in the Global Transdermal Drug Delivery System Market?
7. What modes and strategic moves are considered suitable for entering the Global Transdermal Drug Delivery System Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Application Outlook
3.4. Type Outlook
3.5. End User Outlook
3.6. Region Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers Rising Prevalence of Chronic Diseases Coupled with Increasing Geriatric Population Surging Adoption of Third Generation Transdermal Drug Delivery System Growing Technological Advancements in Transdermal Drug Delivery System
5.1.2. Restraints Technical Concerns Over Irritation or Skin Sensitivity
5.1.3. Opportunities Emerging Introduction and Application of Automated Drug Delivery Systems Ongoing Inorganic Growth Strategies such as Partnerships between Pharmaceutical Companies and Drug Delivery Vendors
5.1.4. Challenges Probable Risk of Drug Failure and Recalls
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Transdermal Drug Delivery System Market, by Application
6.1. Introduction
6.2. Cardiovascular Diseases
6.3. Central Nervous System Disorders
6.4. Hormonal Applications
6.5. Pain Management
6.6. Transdermal Estrogen Therapy

7. Transdermal Drug Delivery System Market, by Type
7.1. Introduction
7.2. Transdermal Patches
7.2.1. Drug-In-Adhesive Patches
7.2.2. Matrix Patches
7.2.3. Microneedle Patches
7.2.4. Reservoir Membrane Patches
7.3. Transdermal Semisolids
7.3.1. Gels
7.3.2. Ointments
7.3.3. Sprays

8. Transdermal Drug Delivery System Market, by End User
8.1. Introduction
8.2. Home Care Settings
8.3. Hospitals & Clinics

9. Americas Transdermal Drug Delivery System Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Transdermal Drug Delivery System Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Thailand

11. Europe, Middle East & Africa Transdermal Drug Delivery System Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. 3M Company
13.2. Bayers AG
13.3. Boehringer Ingelheim International GmbH
13.4. Endo International, Inc.
13.5. Glaxosmithkline PLC
13.6. Hisamitsu Pharmaceutical Co., Inc.
13.7. IBSA Farmaceutici Italia Srl
13.8. Johnson & Johnson
13.9. Katecho, LLC
13.10. Lavipharm S.A.
13.11. Lead Chemical Co.,Ltd.
13.12. Luye Pharma Group
13.13. Manchester BIOGEL
13.14. Nitto Denko Corporation
13.15. Novartis International AG
13.16. Nutriband Inc.
13.17. UCB S.A.
13.18. Viatris Inc.

14. Appendix

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting